• Something wrong with this record ?

Epoxylipids and soluble epoxide hydrolase in heart diseases

JD. Imig, L. Cervenka, J. Neckar

. 2022 ; 195 (-) : 114866. [pub] 20211202

Language English Country Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc22011426

Grant support
R01 DK103616 NIDDK NIH HHS - United States
R01 DK126452 NIDDK NIH HHS - United States

Cardiovascular and heart diseases are leading causes of morbidity and mortality. Coronary artery endothelial and vascular dysfunction, inflammation, and mitochondrial dysfunction contribute to progression of heart diseases such as arrhythmias, congestive heart failure, and heart attacks. Classes of fatty acid epoxylipids and their enzymatic regulation by soluble epoxide hydrolase (sEH) have been implicated in coronary artery dysfunction, inflammation, and mitochondrial dysfunction in heart diseases. Likewise, genetic and pharmacological manipulations of epoxylipids have been demonstrated to have therapeutic benefits for heart diseases. Increasing epoxylipids reduce cardiac hypertrophy and fibrosis and improve cardiac function. Beneficial actions for epoxylipids have been demonstrated in cardiac ischemia reperfusion injury, electrical conductance abnormalities and arrhythmias, and ventricular tachycardia. This review discusses past and recent findings on the contribution of epoxylipids in heart diseases and the potential for their manipulation to treat heart attacks, arrhythmias, ventricular tachycardia, and heart failure.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011426
003      
CZ-PrNML
005      
20220506125810.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bcp.2021.114866 $2 doi
035    __
$a (PubMed)34863976
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Imig, John D $u Drug Discovery Center and Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: jdimig@mcw.edu
245    10
$a Epoxylipids and soluble epoxide hydrolase in heart diseases / $c JD. Imig, L. Cervenka, J. Neckar
520    9_
$a Cardiovascular and heart diseases are leading causes of morbidity and mortality. Coronary artery endothelial and vascular dysfunction, inflammation, and mitochondrial dysfunction contribute to progression of heart diseases such as arrhythmias, congestive heart failure, and heart attacks. Classes of fatty acid epoxylipids and their enzymatic regulation by soluble epoxide hydrolase (sEH) have been implicated in coronary artery dysfunction, inflammation, and mitochondrial dysfunction in heart diseases. Likewise, genetic and pharmacological manipulations of epoxylipids have been demonstrated to have therapeutic benefits for heart diseases. Increasing epoxylipids reduce cardiac hypertrophy and fibrosis and improve cardiac function. Beneficial actions for epoxylipids have been demonstrated in cardiac ischemia reperfusion injury, electrical conductance abnormalities and arrhythmias, and ventricular tachycardia. This review discusses past and recent findings on the contribution of epoxylipids in heart diseases and the potential for their manipulation to treat heart attacks, arrhythmias, ventricular tachycardia, and heart failure.
650    _2
$a zvířata $7 D000818
650    _2
$a srdeční arytmie $x farmakoterapie $x enzymologie $x metabolismus $7 D001145
650    _2
$a inhibitory enzymů $x terapeutické užití $7 D004791
650    _2
$a epoxid hydrolasy $x antagonisté a inhibitory $x metabolismus $7 D004851
650    _2
$a epoxidové sloučeniny $x chemie $x metabolismus $7 D004852
650    _2
$a mastné kyseliny $x metabolismus $7 D005227
650    _2
$a nemoci srdce $x farmakoterapie $x enzymologie $x metabolismus $7 D006331
650    _2
$a srdeční selhání $x farmakoterapie $x enzymologie $x metabolismus $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a infarkt myokardu $x farmakoterapie $x enzymologie $x metabolismus $7 D009203
650    _2
$a rozpustnost $7 D012995
650    _2
$a komorová tachykardie $x farmakoterapie $x enzymologie $x metabolismus $7 D017180
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Cervenka, Ludek $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Neckar, Jan $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Laboratory of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic
773    0_
$w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 195, č. - (2022), s. 114866
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34863976 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506125803 $b ABA008
999    __
$a ok $b bmc $g 1789157 $s 1162624
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 195 $c - $d 114866 $e 20211202 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
GRA    __
$a R01 DK103616 $p NIDDK NIH HHS $2 United States
GRA    __
$a R01 DK126452 $p NIDDK NIH HHS $2 United States
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options